Roche enters diabetes drug market

Roche, one of the most powerful pharmaceutical companies in the world, are set to enter the $21 billion per annum diabetes market . The company is understood to be racing to enter the market, after revolutionising the way in which doctors treat cancers .
Roche are stepping up a challenge to diabetic industry leaders Eli Lilly and Novo Nordisk, who are the largest global marketers of insulin . Roche will enter the market with diabetes drugs that make daily injections unnecessary.
Experts forecast that diabetes treatment revenue will soar by over 50 per cent in the next twenty years. Currently, Roche are testing a number of treatments to enter the diabetic market .
Innovative new products, including a peptide-1 analogue that requires just one weekly injectio, are expected to be on the market soon.